Showing 3031-3040 of 3946 results for "".
- Acne Insights: Strategies and Solutions at 2024 SDPA Fallhttps://practicaldermatology.com/news/acne-insights-strategies-and-solutions-2024-sdpa-fall/2468634/The SDPA’s 22nd Annual Fall Dermatology Conference was held last week at the Fontainebleau in Las Vegas. Conference Medical Director Hilary Baldwin, MD, joined Shanna Miranti, MPAS, PA-C, in a discussion called “Acne Insights: Expert Strategies and Solutions from the Pros.” The presentatio
- Xylazine Wounds: Chronicity Linked to Necrosishttps://practicaldermatology.com/news/xylazine-wounds-chronicity-linked-necrosis/2468631/Xylazine-associated wounds frequently present on extremities with necrotic wound beds and increase in severity with chronicity, according to a systematic case series published in JAMA Dermatology. The case series was conducted across three academic hospitals looking at clinical characteris
- Study Links Severe AD With Need for Surgery in Glaucoma Patientshttps://practicaldermatology.com/news/study-links-severe-ad-need-surgery-glaucoma-patients/2468562/Patients suffering from both severe atopic dermatitis (AD) and glaucoma are increasingly likely to need surgical intervention for the glaucoma depending on the severity of their AD, according to a new Journal of Glaucoma study. “Association of Atopic Dermatitis and Risk of Glaucoma Surgery
- T-VASI and F-VASI Shown Reliable in Nonsegmental Vitiligo Assessmenthttps://practicaldermatology.com/news/t-vasi-and-f-vasi-shown-reliable-nonsegmental-vitiligo-assessment/2468550/New research confirmed that the Total Vitiligo Area Scoring Index (T-VASI) and the Facial VASI (F-VASI) are reliable and valid tools for measuring meaningful improvement in patients with nonsegmental vitiligo. The study, published in JAMA Dermatology, included 164 adult participa
- New AD Research Indicates 'New Standards of Care'https://practicaldermatology.com/news/new-ad-research-indicates-new-standards-care/2468544/The bar has been raised for atopic dermatitis (AD). That was the message in “Is EASI 75 Good Enough or Can We Do Better? Elevating Efficacy and Long-Term Safety With JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis,” a presentation from Drs. Christopher Bunick, Brad Glick, and Alexandra Gol
- FDA Approves Emrosi for Rosaceahttps://practicaldermatology.com/news/fda-approves-emrosi-rosacea-treatment/2468543/The US Food and Drug Administration (FDA) has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) as a treatment for inflammatory lesions of rosacea in adults. According to a press release from the manufacturer, Journey Medical (in partnership with Dr.
- Deuruxolitinib Shows Efficacy in Adults with Severe Alopecia Areatahttps://practicaldermatology.com/news/deuruxolitinib-shows-efficacy-adults-severe-alopecia-areata/2468485/New findings on LEQSELVI™ (deuruxolitinib) presented at the 44th Annual Fall Clinical Dermatology Conference showed sustained efficacy and safety in adults with severe alopecia areata (AA). According to a press release from the manufacturer, the FDA-approved JAK inhibitor showed meaningfu
- Promising Pipeline for CSU Optionshttps://practicaldermatology.com/news/promising-pipeline-csu-options/2468488/Cleveland Clinic allergist Dr. David Lang joined Dr. Dawn Merritt and Dr. Brad P. Glick to discuss chronic spontaneous urticaria (CSU) at the 44th Annual Fall Clinical Dermatology Conference and noted that the future is very promising. “Our recent understanding of chronic urticaria has imp
- Botox Approved for Platysma Bandshttps://practicaldermatology.com/news/botox-approved-platysma-bands/2468436/The US Food and Drug Administration (FDA) has approved BOTOX® Cosmetic for temporary improvement in the appearance of moderate-to-severe vertical bands connecting the jaw and neck (platysma bands) in adults, Allergan Aesthetics, an AbbVie company, announced. According to a press release, B
- Dupilumab Shows Superior Drug Survival in Pediatric Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/dupilumab-shows-superior-drug-survival-pediatric-atopic-dermatitis-treatment/2468431/New research shows dupilumab was superior drug survival compared to methotrexate (MTX) and cyclosporine A (CsA) in pediatric patients with atopic dermatitis (AD), and with lower rates of treatment discontinuation. The study, published in JAMA Dermatology, conducted across five ter